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S U M M A R Y
Nodding syndrome is a devastating neurological disorder, mostly affecting children in eastern Africa. An
estimated 10 000 children are affected. Uganda, one of the most affected countries, set out to
systematically investigate the disease and develop interventions for it. On December 21, 2015, the
Ministry of Health held a meeting with community leaders from the affected areas to disseminate the
results of the investigations made to date. This article summarizes the presentation and shares the story
of studies into this peculiar disease. It also shares the results of preliminary studies on its pathogenesis
and puts into perspective an upcoming treatment intervention. Clinical and electrophysiological studies
have demonstrated nodding syndrome to be a complex epilepsy disorder. A deﬁnitive aetiological agent
has not been established, but in agreement with other affected countries, a consistent epidemiological
association has been demonstrated with infection by Onchocerca volvulus. Preliminary studies of its
pathogenesis suggest that nodding syndrome may be a neuroinﬂammatory disorder, possibly induced
by antibodies to O. volvulus cross-reacting with neuron proteins. Histological examination of post-
mortem brains has shown some yet to be characterized polarizable material in the majority of
specimens. Studies to conﬁrm these observations and a clinical trial are planned for 2016.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
Nodding syndrome is a devastating neurological disorder. First
reported in Tanzania in the 1960s,1 subsequent reports have come
from South Sudan2–4 and Uganda.5,6 An estimated 10 000 children
are affected in these three countries, of whom 3320 are in Uganda.
In 2012, the Government of Uganda put together a multisector
programme to address the disease. The programme included
research to better characterize the disease, develop interventions,
and determine the cause. The Government also engaged the World
Health Organization (WHO), the United States Centers for Disease
Control and Prevention (US CDC), and the United Kingdom
Department for International Development, and together with* Corresponding author.
E-mail address: ridro1@gmail.com (R. Idro).
http://dx.doi.org/10.1016/j.ijid.2016.03.002
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).representatives from local and foreign universities, organized a
scientiﬁc conference in 2012. At this conference, plans for the
investigations were improved and resources shared, and these
collaborations enabled input into the studies shared in this article .
This article summarizes ﬁndings from the research, shares
preliminary studies on the pathogenesis, and reports upcoming
interventions. The work of local organizations involved in the
rehabilitation of patients is also discussed.
2. Clinical features and complications of nodding syndrome
In affected persons, nodding syndrome is characterized by
bouts of repetitive head nodding. Symptoms develop in children
with previously normal development aged 3 to 18 years. Head
nodding is the pathognomonic feature of nodding syndrome. The
head nodding often occurs in association with feeding, a coldciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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tonic–clonic, focal motor, myoclonic, and atypical absence
seizures, behavioural difﬁculties, declining cognitive and motor
function, wasting, growth failure, and physical deformities, leading
to severe disability and in some cases death. Psychiatric symptoms
are also common, including depression and generalized anxiety,
emotional symptoms, wandering, disorientation, and aggressive
behaviour, and in some cases, disorganized behaviour with
psychotic features.
The interictal electroencephalogram (EEG) is characterized by
generalized slow wave activity, and multiple interictal epilepti-
form discharges are seen. Ictal activity consists of mostly
generalized spike and spike and wave discharges.6,7,9,10 The EEG
and electromyogram (EMG) ﬁndings suggest that the head
nodding may be atonic seizures.6 In Tanzania, electrical patterns
of atypical absences have also been observed.11 Head nodding may
also be induced by hyperventilation.10 Available neuroimaging has
mostly been obtained using low-resolution 0.2–0.5 T magnetic
resonance imaging (MRI) and has shown generalized cerebral
cortical and cerebellar atrophy. Non-speciﬁc gliotic changes and
hippocampal atrophy have also been described in some chil-
dren.6,7,9,12
It has been determined that the complications of nodding
syndrome in untreated patients may develop through ﬁve clinical
stages,9 which provide potential opportunities for interventions to
arrest progression (Figure 1).
3. Treatment and treatment outcomes
There is currently no speciﬁc treatment for nodding syndrome.
With careful observations of small numbers of patients hospital-
ized for a few weeks, symptoms and signs amenable to
symptomatic relief have been identiﬁed and a package of
symptomatic therapies for care has been developed by the present
researchers. A training manual has also been developed and this
manual has been used to train health workers deployed to care for
the patients.
Treatment aims at symptom relief and includes the use of
sodium valproate for seizures and nutritional, behavioural, and
physical therapy.13 Patients now receive this care at 17 nodding
syndrome treatment centres across the affected region (Figure 2).
The outcomes of the intervention were audited in approximately
500 patients about a year after the initiation of treatment and
signiﬁcant improvements in seizure control, function, and quality
of life were demonstrated.14 With these improvements, about 40%
had returned to school. Thus, it would appear that patients
receiving appropriate antiepileptic treatment may not go through
all ﬁve clinical stages of nodding syndrome and cognitive function
may improve with seizure control. There have, however, been
challenges with the supply of antiepileptic drugs, and theStage 1
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Figure 1. The natural history of nodding syndrome. Preliminary studies suggest that
the symptoms and complications of nodding syndrome develop through ﬁve
distinct but overlapping clinical stages over several years.treatment centres have at times experienced stock-outs. This
problem has decreased over time.
4. The aetiology of nodding syndrome
In trying to understand the aetiology of nodding syndrome,
three questions were posed: Is nodding syndrome caused by a
toxin or chemical? Is it a genetic disorder? Is it caused by an
infection?
4.1. Is nodding syndrome caused by a toxin or chemical in the
environment, or water or food eaten in the area? Is it related to
chemicals used during the war that took place here?
The affected areas of northern Uganda and South Sudan have
experienced long periods of warfare, exposure to war chemicals,
and large internal population displacements. In the displaced
people’s camps, other than local food sources, food in the camps
was supplied by the World Food Programme. However, the
affected area in Tanzania experienced no such war or population
displacement, raising doubts about the association with war or
food relief. Moreover, although reports of nodding syndrome in
northern Uganda started in 1997, cases increased rapidly from
2001, with peaks in 2003–2005 and 2008, 5–6 years after peaks in
the number of wartime conﬂicts.15 All the same, a series of studies
of potential toxins was undertaken by investigators from the
Ministry of Health, the US CDC, and local universities. Body ﬂuids
and tissue samples were obtained from cases and unaffected
controls. None of the studies identiﬁed a speciﬁc toxin, however a
vitamin B6 deﬁciency was present in the majority of cases (84%)
and controls (75%).16–18 Exposure to potential fungal contaminants
in food could not, however, be excluded in the studies in South
Sudan.19
4.2. Is nodding syndrome a genetic disorder?
The clustering of cases in selected areas and communities
would suggest a geographically bounded exposure or genetic
susceptibility. The case for a genetic cause became even stronger
when it was observed that in over 60% of homes with cases,
more than one child was affected (R. Idro, unpublished).
However, it was clear from discussions with older members
of the affected community that nodding syndrome was a
relatively new disease within their community; a disease with
similar presentation had not been observed in the Acholi land
before the 1990s. With regard to the potential involvement of a
recessive disorder, the affected communities do not practice
consanguineous marriages . More speciﬁcally, investigators from
the CDC performed exome sequencing on two children, one
Ugandan and one South Sudanese, and found no association
with known epilepsy genes.18
4.3. Is it caused by an infection?
Unlike Tanzania, the disease in Uganda and South Sudan has had
the pattern of an epidemic, with very many children affected within
a deﬁned area and in short time. However, whatever the agent, the
disease is unlikely infectious (i.e., unlikely to spread from one person
to another), as nodding syndrome only develops in children. In a
detailed epidemiological study of cases in Kitgum, Foltz et al.
investigated the relationship between nodding syndrome and
current or previous exposure to several infections and infestations,
including cysticercosis, trypanosomiasis, malaria, and measles; no
association was demonstrated with each of these.16,18 Studies by the
US CDC found no relationship with 19 different virus families.18 The
affected age group, the duration of symptoms, and the EEG
Figure 2. Map showing the locations of 17 specialized nodding syndrome treatment centres across northern Uganda. The map shows the locations of the 17 treatment centres
in the seven districts of Oyam, Lira, Gulu, Amuru, Pader, Kitgum, and Lamwo.
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unlikely.7,9 Indeed, no evidence of prion disease has been observed
on histology. However, a strong epidemiological association has
been documented between nodding syndrome and infection with
Onchocerca volvulus (Table 1 3,16,20) (reviewed in Dowell et al.18).
O. volvulus has also been associated with other forms of
epilepsy.21 The nodding syndrome affected region in Uganda is
crossed by the rivers Aswa and Pager and is endemic for O.
volvulus. Global positioning systems (GPS) mapping of cases of
nodding syndrome in the three most affected districts of Pader,
Kitgum, and Lamwo shows dense clustering of nodding syndrome
cases along the same rivers (Joseph Wamala et al., unpublished).
However, the overlap with a similar mapping of other cases of
epilepsy was incomplete (Figure 3). It is possible that some of the
‘other forms of epilepsy’ are cases of onchocerciasis-associated
epilepsy and therefore located close to the Aswa and Pager rivers,
while epilepsy cases further away from these rivers have another
aetiology.Table 1
Infection by Onchocerca volvulus and nodding syndrome
Country and area of study Test method Cases, n/N (% positiv
South Sudan, Amadi, 2001 Skin snip 29/30 (96.7%) 
South Sudan, Lui, 2001 Skin snip 35/39 (89.7%) 
South Sudan, Lui, 2002 Skin snip 12/13 (92.3%) 
Uganda, Kitgum, 2009 ELISA 37/39 (94.9%) 
South Sudan, Witto and Maridi, 2010 Skin snip 29/38 (76.3%) 
OR, odds ratio; CI, conﬁdence interval; CDC, US Centers for Disease Control and PrevenDespite the consistent association, it is unclear how O. volvulus
may cause nodding syndrome and several questions have been
asked. First, this parasite is endemic in many parts of Africa, Latin
America, and Asia where it causes river blindness, yet nodding
syndrome has only been reported in a few areas of Africa. Secondly,
only children are affected. Third, it is unclear how the parasites can
cause brain injury as there is hardly any evidence of breach of the
blood–brain barrier and none has ever been demonstrated in brain
tissue or in cerebrospinal ﬂuid.7 Alternative mechanisms other
than direct parenchymal injury are likely.
4.4. Cross-reacting antibodies, complex epilepsy, and the
pathogenesis of nodding syndrome
Antibodies against neuron surface proteins such as the voltage-
gated potassium channel complex (VGKC), the N-methyl-D-
aspartate (NMDA), a-amino-3-hydroxy-5-methyl-4-isoxazolepro-
pionic acid (AMPA), gamma-aminobutyric acid (GABA)A, GABAB,e) Controls, n/N (% positive) OR (95% CI) Reference
17/34 (50.0%) 29 (3.5, 238) Tumwine et al.20
15/31 (48.4%) 9.3 (2.6, 32.6) Tumwine et al.20
7/16 (43.8%) 15.4 (1.6, 149) Tumwine et al.20
20/41 (48.8%) 14.4 (2.7, 78) Foltz et al.16
18/38 (47.4%) 3.2 (1.2, 8.7) CDC3
tion.
Figure 3. GPS locations of individual patients with nodding syndrome or other forms of epilepsy in the three most affected districts of Kitgum, Pader, and Lamwo in northern
Uganda. The maps are similar, but the overlap is incomplete. (a) Cases of nodding syndrome are highly clustered along the Aswa and Pager river banks. (b) Patients with other
forms of epilepsy are also clustered, but the overlap in the distribution with cases of nodding syndrome is incomplete.
R. Idro et al. / International Journal of Infectious Diseases 45 (2016) 112–117 115and glycine receptors are recognized causes of severe epileptic
disorders.22 Patients have seizures, psychiatric features, and
progressive encephalopathy. Preceding infections may possibly
play a role through molecular mimicry or indirectly by inducing
cytokines and allowing pathogenic antibodies to gain access to the
brain (reviewed by Vincent et al.22,23). It is hypothesized that
nodding syndrome, which was previously unknown and is not
universal in all O. volvulus endemic areas, is a neuroinﬂammatory
disorder caused by antibodies to either O. volvulus or its co-
symbiotic bacteria, Wolbachia, cross-reacting with host neuron
surface proteins, although evidence for neuroinﬂammation has not
been forthcoming.6
4.5. Preliminary studies show evidence of neuroinﬂammation in
nodding syndrome
The hypothesis of neuroinﬂammation in nodding syndrome has
been supported by two separately conducted studies .
In the ﬁrst study, and as part of a 2013 community survey of
215 nodding syndrome patients to describe the complications of
nodding syndrome, serum samples were obtained from 31 nod-
ding syndrome patients with O. volvulus infection on micro-
scopic examination of skin snips (microﬁlaria parasite density of
1–20 parasites/ml in saline in which the skin snips had been
incubated overnight). Serum samples were also obtained from
11 nodding syndrome unaffected siblings. Both sets of samples
were tested for the presence of antibodies against the neuron
surface protein – VGKC complex protein – at the University of
Oxford Neuro-Immunology Laboratory. A positive test was
deﬁned as an antibody level greater than 150 pmol/l. Fifteen
of the 31 cases (48.3%) and one of the 11 controls (9.1%) tested
positive (p = 0.03) (R. Idro et al., unpublished). No patient or
control subject had antibodies to the intracellular glutamic
acid decarboxylase, which is also associated with complex
epilepsy.
An earlier pilot study of Tanzanian patients did not ﬁnd
antibodies to the VGKC complex proteins.24 There were, however,
concerns with the Tanzanian study, particularly the inclusion of
only patients who had samples left over after several years of
storage and multiple thaw and freeze cycles, and the use of
commercial tests for speciﬁc VGKC proteins, which do not have the
same sensitivities. The results so far do not yet indicate antibodies
to a speciﬁc component of the VGKC complex protein.In the second study, investigators at the US CDC and the
National Institutes of Health used a protein array to proﬁle
autoantibodies in 19 nodding syndrome cases and 19 unaffected
controls. This approach detected a >1.5-fold increase in antibodies
to 167 probes representing 137 individual proteins in pooled
patient sera compared to controls. Speciﬁcally, antibodies to
leiomodin 1 were increased in 11/19 (58%) cases vs. 5/19 (26%)
controls.25 Leiomodin is better known as a muscle protein, but the
localization of leiomodin 1 in mouse brain has shown it to be
focally expressed in cortical neurons, in Purkinje cells in the
cerebellum, and in the CA3 region of the hippocampus. All three
areas have been shown to suffer atrophy on brain MRI in earlier
studies.7,9,12 Antibodies to leiomodin 1, which shares 83%
sequence similarity with a conserved region of O. volvulus
tropomyosin, were neurotoxic in vitro to mouse brain and showed
cross-reactivity to O. volvulus tropomyosin, supporting the
hypothesis that a neuropathology in nodding syndrome may be
caused by cross-reacting antibodies.
Although yet to be investigated, pathological host inﬂammatory
responses in O. volvulus-infected individuals may also be against
Wolbachia. Wolbachia are intracytoplasmic symbiotic bacteria
found in ﬁlarial worms. They are essential for the survival,
reproduction, and probably for the pathogenesis of O. volvulus. O.
volvulus extracts depleted of Wolbachia with doxycycline do not
induce the inﬂammation seen in O. volvulus-associated corneal
keratitis.26 Variant species may increase the pathogenicity, and
treatment with tetracyclines could eliminate the tissue injury.27
The identiﬁcation of any such variants could be crucial in
elucidating other targets for intervention. Furthermore, Wolbachia
exist in up to 11 serogroups or super-groups (A–K). Super-groups
A, B, E, H, I, and K are commonly found in arthropods, while groups
C, D, and J are limited to ﬁlariae. It is unknown whether unique
super-groups exist in regions with nodding syndrome and in
patients with nodding syndrome, or whether new and virulent
super-groups have evolved. An investigation of this hypothesis is
part of the proposed studies for 2016 to 2019 (Figure 4).
5. Post-mortem studies
Between 2010 and 2015, post-mortem studies were performed
on children who had died in the districts of Kitgum and Gulu.
Grossly, the post-mortem brains showed signiﬁcant atrophy with
copious cerebrospinal ﬂuid. On histological examination, six of
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Figure 4. Potential immune-pathogenic pathways in the causation of nodding
syndrome.
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the form of polarizable crystal-like materials of different sizes,
mainly in the brainstem, but also in the white matter. There was no
inﬂammatory reaction associated with these materials, but they
apparently dissolved when the brains were stored in 70% alcohol.
What they are and their nature and signiﬁcance are yet to be
established (Dr Sylvester Onzivua, personal communication).
6. Rehabilitation services
A major challenge has been the provision of rehabilitation
services for patients. Although the current guidelines for the
management of patients clearly provide for this, the provision of
this care is still inadequate. Most of the treatment centres do not
have the human resource capacity to provide this service.
However, a local non-governmental organization, Hope for
Humans, has established a model rehabilitation system where
patients receive comprehensive care and rehabilitation. Improve-
ments in functional outcomes with this intervention have been
impressive.
7. Planned studies on the pathogenesis and treatment of
nodding syndrome
Gulu University organized a follow-up meeting to the
2012 conference in August 2015, at which the results of studies
performed at different laboratories were shared. The conference
concluded that reliable neuropathological data and biological
markers for nodding syndrome are urgently needed, especially if
these are present throughout the clinical evolution of nodding
syndrome.11
Currently, there is no speciﬁc treatment for nodding syndrome.
In addition, there is no routine treatment for the adult Onchocerca.
Ivermectin, which kills microﬁlariae, has little if any effect on adult
parasites. Instead, these continue to produce microﬁlariae for a
lifespan lasting 5–15 years.28 Killing the adult worms could
potentially alter the course of nodding syndrome. This may be
achieved by targeting Wolbachia. Antibiotic depletion of Wolba-
chia results in extensive apoptosis in the adult O. volvulus germ-
line and somatic cells of embryos,29 leading to marked reductions
in host dermal microﬁlaria density, sterilization, and premature
death of the adult parasite. Open-label trials have demonstrated
that a 6-week course of oral doxycycline, 100 mg/day, results in a
>90% reduction in Wolbachia levels in ﬁlarial tissue and in dermal
microﬁlaria density over a period of 6–11 months,30,31 and early
death of the adult parasite. The 6-week treatment length is feasible
in the community. In a trial in Cameroon, coverage of 73.8% was
achieved with 97.5% compliance.32 However, the tetracyclines
deposit in growing bone and may cause dental staining andhypoplasia, and thus are contraindicated in children aged <8 years
and in pregnant and breast-feeding women. Rifampicin may be
considered for younger children.33,34 Interaction with sodium
valproate is limited.
The authors have therefore proposed a phase II trial of
doxycycline 100 mg daily for 6 weeks or placebo as treatment
for children with nodding syndrome. Recruitment into this trial
will begin at the end of the ﬁrst quarter of 2016. Concurrently, a
larger case–control study will be conducted to seek evidence of
neuroinﬂammation or cross-reacting antibodies in nodding
syndrome and to determine the effects of doxycycline treatment
on any such inﬂammatory responses. If evidence of neuroin-
ﬂammation and/or speciﬁc autoantibodies or cross-reacting
antibodies is found, immune-modulatory therapies may be
considered. In addition, conﬁrmation of a biological association
between nodding syndrome and infection with O. volvulus would
allow an escalation of treatments and prevention. Indeed, if pilot
studies indicate a potential role for doxycycline, this would offer a
cheap intervention beneﬁcial to the older child. It would also be a
proof of principal that treatment is possible and that similar
strategies can be explored for younger children.
8. Conclusions
Nodding syndrome is a devastating disorder that affects
developing brains and manifests with epilepsy and is complicated
by multiple physical and functional disabilities and psychiatric
manifestations. It is associated with infection with O. volvulus and
may be a neuroinﬂammatory disorder. Much progress has been
made in the care of children in Uganda; symptoms and function
improve with symptomatic treatments. This progress has been
supported by detailed research, and further research is on the way.
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